Biotech Growth Share Discussion Threads

[ali47fish] 06/2/2024 23:07

what is scholae rock please?

[takeiteasy] 06/2/2024 18:15

Scholar Rock on the move again - a rather pretty looking chart (one of our top 10 holdings) - dyor and no advice...

[takeiteasy] 01/2/2024 13:36

From the holdings in IT noted in the annual report(may not be fully up to date and excluding any fallers) just YTD 2024 performance i.e. month of January alone:

Vera up 137%, Edgewise up 63%, Keros up 40%, Mersana up 36%, GH up 30% etc etc so my sense is that some of the star performers here are coming out of hibernation and back to life and hopefully a much better outlook for the year ahead.

I have not added the 1/3 year comparatives as we all know the recent past has been poor so I am trying to look forward and not back :)

dyor and no advice etc...

[daveoz1] 01/2/2024 08:26

Thanks takeiteasy, I really need some good news at last about Biotech Growth since its disastrous share price run for 16 months after Feb 2021...!

[takeiteasy] 01/2/2024 07:45

2seventybio is one of the investments in this trust - just caught my interest as whilst it is only one from a long list of investments, it seems to have had an unusual share price move...
hxxps://www.2seventybio.com/

[ali47fish] 01/2/2024 07:38

tke please explain what's 2seventybio

[takeiteasy] 31/1/2024 18:50

2seventybio which was a c.3% holding in the annual report is up 38% today. Can't harm the NAV :)
dyor and no advice

[takeiteasy] 25/1/2024 16:41

Helps the cause when one of the holdings is up 43% in one day vera therapeutics. Scholar rock is also an interesting one to follow now in the top 10 holdings list.

dyor and no advice intended

[takeiteasy] 10/1/2024 05:38

Could not agree more, finally being the operative word e.g. the 7 year chart shows we are pretty much flat over the entire period where it appears the US index has been up a small amount - perhaps the very small cap bias has not helped in the distant past but is now seen as a help given the exceptionally low valuations to net cash for many of the smaller companies - would be nice if this is the year for the biotechs...dyor etc

[1c3479z] 09/1/2024 22:20

finally showing some vigour,
seems m and a activity benefiting in the US

[luckymouse] 31/12/2023 09:45

Hard to know where that will go - certainly its coming off a deep technical discount here & will likely rise - but ever since the great 2008 Biotech run, excitement over genome sequencing & other new genetic techniques, its largely been stuck in that consol & gone nowhere. Lot of work to do to get back into trend.
If miraculous new Ai applications start appearing that could turn the sector hot again - perhaps a discounted punt upon that outcome..

free stock charts from uk.advfn.com

[1c3479z] 17/4/2023 16:33

put up a dire performance in March with trouble in China, mainly.

[c3479z1] 13/3/2023 12:49

some slight relief for shareholders from the seagen takeover, apparently 1.7% of assets as of September 2022 and confirmed they were holders in the latest factsheet.

[mozy123] 13/1/2023 16:24

What's moving this today? Any news?

[ali47fish] 16/11/2022 07:54

biog update new chair some improvement

[ali47fish] 08/8/2022 08:34

no dave the share price is coming back

[mozy123] 17/6/2022 15:53

Seagen jumps on report Merck is said to eye possible acquisition

[daveoz1] 14/6/2022 15:47

Quote from above "By the standards of 2008 / 2009, this little Investment Trust has had a reasonably decent year". !!! What does that mean? When was that written? Am I missing something? Since March 2021, the Biotech Growth Trust price has plummeted by 50%! My worst investment by far.

[ali47fish] 14/6/2022 14:42

ned buys 10000 shares

[mozy123] 10/5/2022 12:39

Brutal. Cheap or is this pricing defaults and bankrupcies in the sector?

[ali47fish] 03/2/2022 17:12

can't work out whether rathbone has added or sold some here

[richtea2517] 15/1/2022 16:44

Bought a few Friday

[steeplejack] 09/12/2021 11:31

Questor in Daily Telegraph (9 Dec) recommends BIOG after marked underperformance in 2021.

[steeplejack] 29/11/2021 19:03

Oh dear,not popular comments i see.Thing is,over the last five years,BIOG is up 57%,over the same period SMT is up 375%.Investment is about opportunity cost as we all know.Now compared with Astra or Pfizer,the underperformance is that much less,over five years the former is up 97% and the latter up 77%.(Generously,i217;m ignoring management costs attaching to BIOG.)I’m really trying to justify why,on its track record,i should continue to hold this trust especially given its rather ‘risk averse’construct.It appears to be a rather broad simple proxy for biotech per se which means even a major success of one of the constituents is unlikely to meaningful alter the NAV.